DataVXACS Applied Materials & InterfacesPaper
journal article·2025-01-08

Prolonged Immunomodulator Delivery Boosts Monocyte Exosome Secretion and Elevates Cathelicidin/LL-37 Content

Dezun Ma, Yajuan Su, Navatha Shree Sharma, Grant Hatcher, Gitali Ganguli-Indra, Arup K. Indra, Adrian F. Gombart, Jingwei Xie

ACS Applied Materials & Interfaces· Volume 17· Issue 1
Publisher page
Source abstract

Abstract

Human cathelicidin LL-37 offers significant benefits to the immune system and in treating various diseases, but its therapeutic potential is hindered by low activity and instability in physiological environments. Here, we introduce a strategy to boost LL-37 levels in exosomes derived from THP-1 monocytes by incubating cells with electrospun nanofibers containing immunomodulators (e.g., 1α, 25-dihydroxyvitamin D 3 and VID400). Notably, the incubation with immunomodulator-loaded nanofibers not only increased LL-37 content in exosomes but also significantly enhanced the production of engineered exosomes. Moreover, these engineered exosomes demonstrated multiple biological activities, including promoting skin cell proliferation and migration, enhancing endothelial cell tube formation, and exhibiting antibacterial properties. Collectively, this study presents an approach to increasing both the yield of engineered exosomes and their LL-37 content, potentially offering a promising therapeutic option for wound healing, tissue regeneration, and infectious disease treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Extracellular vesicles in disease · Antimicrobial Peptides and Activities · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Surgery-Transplant and Mary & Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States

Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon 97331, United States

Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon 97239, United States

Department of Dermatology, Oregon Health & Science University, Portland, Oregon 97239, United States

Linus Pauling Institute, Department of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon 97331, United States

Department of Mechanical and Materials Engineering, College of Engineering, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, United States

Funding

University of Nebraska Medical Center · National Institute of General Medical Sciences

References (44)

Show source-provided references
1. 10.3390/antibiotics1006065010.3390/antibiotics10060650 ↗
2. 10.1016/j.bbamem.2015.11.00310.1016/j.bbamem.2015.11.003 ↗
3. 10.1038/s41467-020-17736-x10.1038/s41467-020-17736-x ↗
4. 10.3390/microorganisms1105112910.3390/microorganisms11051129 ↗
5. 10.1007/s12013-024-01448-w10.1007/s12013-024-01448-w ↗
6. 10.1093/burnst/tkae02310.1093/burnst/tkae023 ↗
7. 10.1016/j.ymthe.2017.03.03010.1016/j.ymthe.2017.03.030 ↗
8. 10.1186/s12951-023-02259-610.1186/s12951-023-02259-6 ↗
9. 10.3389/fimmu.2017.0033910.3389/fimmu.2017.00339 ↗
10. 10.1002/stem.54410.1002/stem.544 ↗
11. 10.1016/j.antiviral.2024.10585510.1016/j.antiviral.2024.105855 ↗
12. 10.1002/adhm.20220084910.1002/adhm.202200849 ↗
13. 10.1007/s10565-008-9112-810.1007/s10565-008-9112-8 ↗
14. 10.3390/cancers1402038710.3390/cancers14020387 ↗
15. 10.1016/S0303-7207(01)00406-310.1016/S0303-7207(01)00406-3 ↗
16. 10.1046/j.1365-2265.2000.00909.x10.1046/j.1365-2265.2000.00909.x ↗
17. 10.1021/acs.molpharmaceut.1c0094410.1021/acs.molpharmaceut.1c00944 ↗
18. 10.3390/jcm908238010.3390/jcm9082380 ↗
19. 10.4049/jimmunol.130200510.4049/jimmunol.1302005 ↗
20. 10.3389/fimmu.2013.0014310.3389/fimmu.2013.00143 ↗
21. 10.1146/annurev-cellbio-101512-12232610.1146/annurev-cellbio-101512-122326 ↗
22. 10.1021/acsbiomaterials.4c0085610.1021/acsbiomaterials.4c00856 ↗
23. 10.1038/s12276-024-01201-610.1038/s12276-024-01201-6 ↗
24. 10.1093/stcltm/szae02710.1093/stcltm/szae027 ↗
25. 10.1016/j.biotechadv.2022.10798310.1016/j.biotechadv.2022.107983 ↗
26. 10.1186/s12951-022-01668-310.1186/s12951-022-01668-3 ↗
27. 10.1002/jlb.59.4.55510.1002/jlb.59.4.555 ↗
28. 10.1016/j.jim.2024.11371610.1016/j.jim.2024.113716 ↗
29. 10.1016/j.gendis.2022.03.02110.1016/j.gendis.2022.03.021 ↗
30. 10.1152/ajprenal.00178.201710.1152/ajprenal.00178.2017 ↗
31. 10.1016/j.jsbmb.2017.10.01310.1016/j.jsbmb.2017.10.013 ↗
32. 10.1016/j.actbio.2016.05.00810.1016/j.actbio.2016.05.008 ↗
33. 10.1002/adfm.20220693610.1002/adfm.202206936 ↗
34. 10.1093/oxfordjournals.epirev.a01803310.1093/oxfordjournals.epirev.a018033 ↗
35. 10.1038/s41598-019-51803-810.1038/s41598-019-51803-8 ↗
36. 10.1038/sj.jid.570104310.1038/sj.jid.5701043 ↗
37. 10.1186/s40779-020-00249-510.1186/s40779-020-00249-5 ↗
38. 10.1016/j.ijpharm.2023.12344210.1016/j.ijpharm.2023.123442 ↗
39. 10.1039/C8BM00807H10.1039/C8BM00807H ↗
40. 10.4049/jimmunol.175.7.466210.4049/jimmunol.175.7.4662 ↗
41. 10.1016/j.peptides.2024.17118310.1016/j.peptides.2024.171183 ↗
42. 10.1172/JCI1754510.1172/JCI17545 ↗
43. 10.1111/jre.1282310.1111/jre.12823 ↗
44. 10.1159/00017153310.1159/000171533 ↗